Keryx Biopharmaceuticals keryx.com


Public list: BIO 2016 (619) Pharma Startups (4740) Cancer Therapeutics (1146)

Keryx Biopharmaceuticals is working to identify medicines to advance the care of people with kidney disease. The company has assembled a concentration of kidney care, including nephrologists, renal dietitians, nurses and industry veterans in nephrology. In September 2014, the U.S. Food and Drug Administration approved Keryx's first medicine, Auryxia (ferric citrate) tablets.

Keryx Biopharmaceuticals is working to identify medicines to advance the care of people with kidney disease. The company has assembled a concentration of kidney care, including nephrologists, renal dietitians, nurses and industry veterans in nephrolo...Show all

Company (Acquired)

Phone: 617-466-3500

Fax:

One Marina Park Drive
12th Floor
Boston, 02210
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Keryx Biopharmaceuticals $87M Jun 28, 2018
See all 29 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Keryx Biopharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 21 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

YM BioSciences

Mississauga, Ontario, Canada
AcquiredYM BioSciences is a life sciences product development company advancing a diverse portfolio of hematology and cancer-related products at various stages of development. In February 2013, YM BioSciences was acquired by Gilead Sciences. The valuation of YM BioSciences was undisclosed. Other terms of the deal were not released.Login to see details

ARIAD Pharmaceuticals

Cambridge, Massachusetts, United States
AcquiredARIAD is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. Our pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites. Our lead candidate �� ridaforolimus, a novel mTOR inhibitor �� has been given fast trac...Show allLogin to see details
See all 29 competitors